BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1767307)

  • 1. [Polymer-drug complexes in the treatment of extensive ovarian cancer].
    Novikova EG; Borisov VI; Dmitriev DG; Zel'vin BM; Karseladze AI; Shchitkov KG; Li AD
    Sov Med; 1991; (11):27-9. PubMed ID: 1767307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of cytostatics deposited in cellulose acetate microspheres in the treatment of ovarian cancer].
    Rusakov IG; Chissov VN; Antoshechkina ET; Dmitriev DG; Ze'lvin BM
    Sov Med; 1989; (10):37-9. PubMed ID: 2694381
    [No Abstract]   [Full Text] [Related]  

  • 3. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V; Ilijas M; Krusić J; Kolarić K
    Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract]   [Full Text] [Related]  

  • 4. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
    Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
    Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
    [No Abstract]   [Full Text] [Related]  

  • 5. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
    Mäenpää J
    Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metastatic brain tumor after chemotherapy of ovarian cancer].
    Fukuda K; Chen JT; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Sakamoto A
    Gan No Rinsho; 1987 Jan; 33(1):115-8. PubMed ID: 3102810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate].
    Chylak V; Kolarić K; Krusić J
    Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515
    [No Abstract]   [Full Text] [Related]  

  • 9. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
    Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical trial of cisplatin in the treatment of ovarian carcinoma].
    Yoshizawa H; Kanazawa K; Takeuchi S; Okamura Y; Goto S; Kajiwara T
    Gan To Kagaku Ryoho; 1982 May; 9(5):822-30. PubMed ID: 6764112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M; Huang X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
    Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer.
    Izbicki RM; Baker LH; Samson MK; McDonald B; Vaitkevicius VK
    Cancer Treat Rep; 1977 Nov; 61(8):1573-5. PubMed ID: 922760
    [No Abstract]   [Full Text] [Related]  

  • 15. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of carboplatin based combination chemotherapy on ovarian cancer.
    Feng Y; Zhang X; Sun H
    Chin Med J (Engl); 1996 May; 109(5):349-52. PubMed ID: 9208489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
    Sessa C; Bolis G; Valente I; Mangioni C; D'Incalci M
    Cancer Treat Rep; 1981; 65(1-2):172-3. PubMed ID: 6784922
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies of second-look operations (SLO) in ovarian cancer].
    Yuzawa H
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.